What is included in the long-term monitoring of Burkitt lymphoma/Burkitt-like lymphoma (BL/BLL)?

Updated: Dec 20, 2019
  • Author: Ali H Kanbar, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

When patients with Burkitt lymphoma receive treatment in the clinic, close monitoring of their white blood cell (WBC) count, hemoglobin, platelet count, serum chemistry levels, and liver functions is needed.

After chemotherapy is completed, patients should be monitored at least every 2 months during the first year, then every 3 months the following year, and every 6 months thereafter.

During follow-up visits, a complete physical examination should be performed, and CBC count and serum electrolyte levels should be obtained. Lactate dehydrogenase (LDH) and beta2 microglobulin studies may be helpful in detecting early relapse.

Repeat staging with computed tomography (CT) scanning is performed during and after completion of treatment to ascertain disease response and document achievement of complete remission.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!